CRISPR LDL cholesterol therapy

There's a lot of media buzz around this, so here's the quick summary. A one-time gene-editing treatment lowered LDL cholesterol and triglycerides by about 50% in patients who received the highest dose, and the effect persisted for at least one year — suggesting a single treatment could potentially replace years of daily pills or repeated injections down the road. The therapy uses CRISPR gene editing to switch off ANGPTL3 in the liver, mimicking naturally occurring gene variants that are associated with very low cholesterol and lower cardiovascular risk. A separate gene-editing approach reported similarly substantial LDL reductions earlier in 2026, adding momentum to the "one-and-done" cholesterol concept. Important caveats: this was a very small, early-stage safety study — only 15 patients, with just four receiving the highest dose. It's far too early to know the long-term safety or whether it actually reduces cardiovascular events. Because gene editing may have permanent effects, participants in these trials will be followed for 15 years for safety, and larger trials are still underway. Experts estimate that if those larger trials confirm safety and benefit, these treatments might become clinically available in the early 2030s. Bottom line: This is a very exciting proof-of-concept for permanent cholesterol lowering, but it's still experimental. It does not replace proven therapies like statins, ezetimibe, PCSK9 inhibitors, or other current LDL-lowering treatments today.